Pieris Pharmaceuticals (NASDAQ:PIRS) Raised to Hold at StockNews.com

Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Pieris Pharmaceuticals Trading Up 2.7 %

Shares of PIRS stock opened at $16.01 on Tuesday. Pieris Pharmaceuticals has a 12-month low of $6.20 and a 12-month high of $22.32. The business’s 50 day moving average is $16.54 and its two-hundred day moving average is $13.85. The company has a market capitalization of $21.13 million, a P/E ratio of -1.32 and a beta of 0.66.

Institutional Investors Weigh In On Pieris Pharmaceuticals

An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals comprises approximately 0.4% of BML Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. BML Capital Management LLC owned about 3.19% of Pieris Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.